Patient Resources

IPI-926 for Chondrosarcoma

Infinity Pharmaceuticals activated a global, randomized, phase 2, double-blind trial of IPI-926 in patients with advanced chondrosarcoma. This ongoing trial will determine the safety and activity of IPI-926 compared to placebo in patients with metastatic or locally advanced conventional chondrosarcoma, in whom surgery is no longer an option. To be eligible, participants must be at least 18 years of age, have conventional chondrosarcoma and have experienced progression of their disease within 6 months prior to enrollment. For more details regarding this study, including more complete eligibility criteria and a list of participating centers, please go to the following link: clinical trial overview.

Programs & Resources

Information on sarcoma subtypes, treatments, clinical trials, and other important resources for sarcoma patients and families.

Information on the Sarcoma Patient Registry. If you are diagnosed with sarcoma, please consider joining the Registry.

Information on applying for a sarcoma research grant, current research funded by the SFA, and past research grants.